|
Imipenem
| | | | |
|
Winston et al. 1984 [24]
|
35 patients with infections from imipenem-susceptible organisms
|
4 g/day (23 patients); <4 g/day (12 patients)
|
None
| |
|
Calandra et al. 1985 [17]
|
First 2,516 patients treated; most had significant background disorders
|
<2 g/day, 32 percent; 2 g/day, 44 percent; >2 g/day, 24 percent
|
1.5 percent (37/2,516) all episodes; 0.24 percent (6/2,516) imipenem related
|
High rates of central nervous system disorders in patients with seizures
|
|
Winston et al. 1988 [25]
|
29 febrile granulocytopenic patients
|
1 g q6h
|
10.3 percent (3/29)
|
Versus 0 percent (0/58) treated with 2 β-lactams
|
|
Eng et al. 1989 [4]
|
First 22 patients treated
|
Varied (500 mg q12h to 1 g q6h)
|
22.7 percent (5/22)
| |
|
Rolston et al. 1992 [22]
|
371 febrile neutropenic cancer patients
|
12.5 mg/kg q6h
|
1.5 percent (3/196) imipenem + vancomycin; 3.4 percent (6/175) imipenem + amikacin
|
1 g qh6 for an 80 kg patient
|
|
Norrby et al. 1993 [19]
|
197 patients with severe nosocomial infections
|
500 mg q6h adjusted for renal dysfunction
|
0.5 percent (1/197)
|
Versus 0 percent (0/196) treated with ceftazidime
|
|
Raad et al. 1996 [21]
|
198 febrile neutropenic cancer patients
|
500 mg q6h
|
0.5 percent (1/198) imipenem + vancomycin
|
Versus 0 percent (0/192) treated with aztreonam + vancomycin
|
|
Karadeniz et al. 2000 [18]
|
82 pediatric patients with malignancies
|
50 mg/kg/day in 3 doses
|
3.6 percent (3/82)
| |
|
Koppel et al. 2001 [3]
|
98 patients
|
Max. 2 g/day
|
4.0/1,000 patient-days (on imipenem); 3.9/1,000 patient-days (not on imipenem)
|
No increase in risk due to imipenem
|
|
Winston et al. 2001 [94]
|
541 febrile granulocyto-penic patients
|
500 mg q6h
|
2 percent
|
0 percent for clinafloxacin (200 mg every 12 h); P = 0.06
|
|
Meropenem
| | | | |
|
Sieger et al. 1997 [96]
|
104 patients with noso-comial lower respiratory tract infections
|
1 g q8h
|
2.9 percent (3/104) all episodes; 0 percent meropenem related
| |
|
Norrby et al. 1999 [29]
|
4,872 patients in multiple trials
|
0.5 to 1 g q8h
|
Meropenem related: 0.08 percent (patients without meningitis); 0 percent (patients with meningitis)
| |
